# Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML

- Source: PR Newswire M&A
- Published: 2026-11-04T14:05:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-ash-2026-abstract-highlighting-long-term-results-of-actimab-a-in-combination-with-clag-m-in-relapsed-or-refractory-aml-302928605.html
- Canonical: https://groundlevelnews.com/story/actinium-pharmaceuticals-announces-ash-2026-abstract-highlighting-long-331e1c/

Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemia Long-term follow-up evaluates bone marrow recovery and potential delayed kidney and liver toxicities following Actimab-A plus intensive salvage...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._